ICH (ICH)

📊 Statistics

Analyst 1 Year Price Target: -
Upside/Downside from Analyst Target: -
Broker Call: -
Dividend Minimum 3 Year Yield: -
EPS Growth Range (1Y): -
Net Income Growth Range (1Y): -
Revenue Growth Range (1Y): -
Upcoming Earnings Date: -

💰 Dividend History

No dividend history available.

📅 SGX Earnings Announcements for ICH

Date of Broadcast	Title	Financial Year Ended

ICH (ICH)

Market: SGX | Currency: SGD

Address:

📈 ICH Historical Chart

🧾 Recent Financial Statement Analysis

Intraco Limited Acquires 80% Stake in SlideSG, Completes iChange Acquisition in Singapore 1

January 2, 2026

Intraco Limited Acquires Majority Stake in Licensed Payment Institution SlideSG (to be renamed iChange Pte Ltd) Intraco Limited Acquires 80% Stake in SlideSG, Marks Strategic Expansion into Payment Services Key Developments Announced Intraco Limited has exercised its Exchange Option, acquiring…

China International Holdings Limited Provides Final Update on Yichang Court Litigation and Impact on Financial Performance

December 11, 2025

China International Holdings Limited: Update on Litigation and Court Hearing China International Holdings Limited: Final Court Judgment on Subsidiaries' Litigation Case China International Holdings Limited ("CIHL" or the "Company") has issued an important update regarding a significant litigation involving its…

Rich Capital Holdings Announces Revised Share Consolidation and Updated Listing Notice from SGX-ST

December 10, 2025

Rich Capital Holdings Limited – Detailed Update on Share Consolidation and Revised SGX-ST Listing Notice Rich Capital Holdings Limited Announces Revised Share Consolidation Figures Following SGX-ST Notice Key Points for Investors Share Consolidation Ratio: Every 200 existing ordinary shares will…

Rich Capital Holdings Limited Extraordinary General Meeting 2025: Share Consolidation Resolution and Results

December 4, 2025

Rich Capital Holdings EGM: Detailed Report on Share Consolidation Rich Capital Holdings Approves Major Share Consolidation at Extraordinary General Meeting Rich Capital Holdings Limited (SGX: Not specified) convened its Extraordinary General Meeting (EGM) on 7 November 2025 at its Paya…

Rich Capital Holdings Strikes Off Dormant Subsidiary Summit Light Ventures Ltd from BVI Register

November 20, 2025

Rich Capital Holdings Limited: Striking-Off of Dormant Subsidiary Rich Capital Holdings Limited Announces Striking-Off of Dormant Subsidiary Summit Light Ventures Ltd Key Points from the Announcement Striking-Off of Subsidiary: Rich Capital Holdings Limited ("Rich Capital" or the "Company") has announced…

🔎 View more in SGX corporate News 🔎 View more in SGX Financial statements

📰 Related News & Research

Showing results matched by any of: ICH

Bob’s Discount Furniture: Growth Strategies, Brand Strength, and Omnichannel Success in the U.S. Home Furnishings Industry 1822103126

January 31, 2026

Bob’s Discount Furniture, Inc. IPO Analysis – January 26, 2026 Bob’s Discount Furniture, Inc. Date of Prospectus: January 26, 2026 Bob’s Discount Furniture IPO: Deep Dive Into America’s Omnichannel Value Retailer’s Landmark NYSE Listing Bob’s Discount Furniture, Inc. is launching…

Sichuan Biokin Pharmaceutical Hong Kong IPO: Innovative Oncology Pipeline, Growth Strategies & Global Expansion (2025 Prospectus Highlights)

January 17, 2026

Baili Pharmaceutical: Hong Kong IPO Analysis, Offer Details, Financials & Outlook Baili Pharmaceutical Co., Ltd. Date of Prospectus: November 7, 2025 Baili Pharmaceutical’s Hong Kong IPO: Key Details, Institutional Interest, Financial Strength, and Investor Outlook IPO Snapshot: Baili Pharmaceutical H…

Sichuan Biokin Pharmaceutical Co., Ltd. Global Offering 2025: IPO Details, Application Process, and Key Dates Explained

January 17, 2026

Sichuan Biokin Pharmaceutical Co., Ltd. IPO Analysis: Key Investor Insights and Listing Outlook Sichuan Biokin Pharmaceutical Co., Ltd. Date of Prospectus: November 7, 2025 Sichuan Biokin Pharmaceutical IPO: A Deep Dive into Offer Structure, Investor Opportunity, and Listing Prospects Sichuan…

Sichuan Biokin Pharmaceutical Hong Kong IPO: Innovative Oncology Drugs, Global Expansion & Key Financials (2025)

January 11, 2026

Baili Pharmaceutical IPO Analysis: Key Details, Financials, Risks, and Outlook Baili Pharmaceutical Co., Ltd. Date of Prospectus: November 7, 2025 Baili Pharmaceutical Hong Kong IPO: Strategic Growth in Oncology, Financials, and Investor Outlook IPO Snapshot Baili Pharmaceutical is launching its…

Sichuan Biokin Pharmaceutical Global Offering 2025: Hong Kong IPO Details, Application Process & Key Dates

January 11, 2026

Sichuan Biokin Pharmaceutical Co., Ltd. IPO Analysis Company Name: Sichuan Biokin Pharmaceutical Co., Ltd. Date of Prospectus: November 7, 2025 Sichuan Biokin Pharmaceutical IPO: In-Depth Analysis, Offer Details, and Investor Insights Sichuan Biokin Pharmaceutical Co., Ltd. (Stock Code: 2615) is…